Paraoxonase (PON1) polymorphism and activity as the determinants of sensitivity to organophosphates in human subjects

Chemico-Biological Interactions

Volumn 168, Issue 3, 2007, Pages 184-192

  Sirivarasai, Jintana ^a   Kaojarern, Sming ^a   Yoovathaworn, Krongtong ^b   Sura, Thanyachai ^a  

^a THAMMASAT UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Acetylcholinesterase; Butyrylcholinesterase; Paraoxonase; Polymorphism

Indexed keywords

ACETYLCHOLINESTERASE; ARGININE; ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; CYSTEINE; DIAZONASE; GLUTAMINE; LEUCINE; METHIONINE; ORGANOPHOSPHATE INSECTICIDE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AMINO ACID SEQUENCE; ARTICLE; CONTROLLED STUDY; ENVIRONMENTAL EXPOSURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME POLYMORPHISM; FEMALE; GENE; GENOTYPE; HAPLOTYPE; HUMAN; HYDROLYSIS; MAJOR CLINICAL STUDY; MALE; PON1 GENE; PROMOTER REGION; SEQUENCE ANALYSIS;

ACETYLCHOLINESTERASE; ADOLESCENT; ADULT; AGED; ARYLDIALKYLPHOSPHATASE; BUTYRYLCHOLINESTERASE; CARBOXYLIC ESTER HYDROLASES; CELLS, CULTURED; CHOLINESTERASE INHIBITORS; ERYTHROCYTES; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; OCCUPATIONAL EXPOSURE; PHOSPHORIC ACID ESTERS; POLYMORPHISM, GENETIC;

EID: 34347252999     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2007.04.006     Document Type: Article

References (31)

1. Thapinta A., and Hudak P.F. Pesticide use and residual occurrence in Thailand. Environ. Monit. Assess. 60 (2000) 103-114
2. PCD (Pollution Control Department), Pollution in Thailand, 1996, Bangkok, Ministry of Science, Technology and Environment, 1997.
3. Maroni M., Colosio C., Ferioli A., and Fait A. Organophosphorus pesticides. Toxicology 143 (2000) 9-37
4. Kamanyire R., and Karalliedde L. Organophosphate toxicity and occupational exposure. Occup. Med. 54 (2004) 69-75
5. Mackness M.I. Possible medical significance of human serum paraoxonase. In: Reiner E., Aldrige W.N., and Hoskin F.C.G. (Eds). Enzymes Hydrolyzing Organophosphorus Compounds (1989), Ellis-Horwood, Chichester, UK pp. 202-213
6. Davies H.G., Richter R.J., Keifer M., Broomfield C.A., Sowalla J., and Furlong C.E. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman, and sarin. Nat. Genet. 14 (1996) 334-336
7. Adkins S., Gan K.N., Mody M., and La Du B.N. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am. J. Hum. Genet. 52 (1993) 598-608
8. Garin M.C., James R.W., Dussoix P., Blanche H., Passa P., Froguel P., and Ruiz J. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J. Clin. Invest. 99 (1997) 62-66
9. Brophy V.H., Jarvik G.P., Richter R.J., Rozek L.S., Schellenberg G.D., and Furlong C.E. Analysis of paraoxonase (PON1) L55M status requires both genotype and phenotype. Pharmacogenetic 10 (2000) 453-460
10. Brophy V.H., Jampsa R.L., Clendenning J.B., Mckinstry L.A., and Furlong C.E. Effect of 5′ regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am. J. Hum. Genet. 68 (2001) 1428-1436
11. Suehiro T., Nakamura T., Inoue M., Shiinoki T., Ikeda Y., Kumon Y., Shindo M., Tanaka H., and Hashimoto K. A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression. Atherosclerosis 150 (2000) 295-298
12. Shih D.M., Gu L., Xia Y.R., Navab M., Li W.F., and Hama S. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394 (1998) 284-287
13. Costa L.G., McDonald B.E., Murphy S.D., Omenn G.S., Richter R.J., Motulsky A.G., and Furlong C.E. Serum paraoxonase and its influence on paraoxon and cholrpyrifos oxon toxicity in rats. Toxicol. Appl. Pharmacol. 103 (1990) 66-76
14. Li W.F., Furlong C.E., and Costa L.G. Paraoxonase protects against chlorpyrifos toxicity in mice. Toxicol. Lett. 76 (1995) 219-226
15. Li W.F., Costa L.G., Richter R.J., Hagen T., Shih D.M., Twadr A., Lusis A.J., and Furlong C.E. Catalytic efficiency determines the in vivo efficacy of PON1 for detoxifying organophosphate. Pharmacogenetics 10 (2000) 767-780
16. Ellman G.L., Courtney D.K., Andres V., and Featherstone R.M. A new rapid colorimetric method determination of acetylcholinesterase activity. Biochem. Pharmacol. 7 (1961) 88-95
17. Whittaker M. Cholinesterase. In: Bergmeyer H.U., Bergmeyer J., and Grabi M. (Eds). Methods of Enzymatic Analysis vol. IV (1984), Verlag Chemie, Weinheim 52-74
18. Phuntuwate W., Suthisisang C., Koanantakul B., Mackness M.I., and Mackness B. Paraoxonase 1 status in Thai population. J. Hum. Gent. 50 (2005) 293-300
19. Campo S., Sardo M.A., Trimarchi G., Bonaiuto M., Fontana L., Castaldo M., Bonaiuto A., Saitta C., Bitto A., Manduca B., Riggio S., and Saitta A. Association between serum paraoxonase (PON1) gene promoter T(-107)C polymorphism, PON1 activity and HDL levels in health Sicilian octogenarians. Exp. Gerontol. 39 (2004) 1089-1094
20. Sole X., Guino E., Vails J., Iniesta R., and Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinformatics 22 (2006) 1928-1929
21. World Health Organization (WHO). Metabolism and Mode of Action. Organophosphate Insecticides: A General Introduction (1986), WHO, Geneva pp. 39-48
22. Ciesielski S., Loomis D.P., Mims S.R., and Auer A. Pesticide exposure, cholinesterase expression, and symptoms among north Carolina migrant farmworkers. Am. J. Public Health 84 (1994) 446-451
23. Ohayo-Mitoko G.J.A., Kromhout H., Simwa J.M., Boleij J.S.W., and Heederik D. Self reported symptoms and inhibition of acetylcholinesterase activity among Kenyan agricultural workers. Occup. Environ. Med. 57 (2000) 195-200
24. Wang X., Huang J., Fan Z., Su S., Zhao J., Shen Y., Qiang B., and Gu D. Genetic and environmental factors associated with plasma paraoxonase activity in healthy Chinese. Int. J. Mol. Med. 13 (2004) 445-450
25. Rao M.N., Marmillot P., Gong M., Palmer D.A., Seeff L.B., Strader D.B., and Lakshman M.R. Light, but not heavy alcohol drinking, stimulates paraoxonase by up regulating liver mRNA in rats and humans. Metabolisms 52 (2003) 1287-1294
26. Rojas-Garcia A.E., Solis-Heredia M.J., Pina-Guzman B., Vega L., Lopez-Carrillo L., and Quintanilla-Vega B. Genetic polymorphisms and activity of PON1 in a Mexican population. Toxicol. Appl. Pharmacol. 205 (2005) 282-289
27. Bryk B., BenMoyal-Segal L., Podoly E., Livnah O., Eisenkraft A., Luria S., Cohen A., Yehezkelli Y., Hourvitz A., and Soreq H. Inherited and acquired interactions between ACHE and PON1 polymorphisms modulate plasma acetylcholinesterase and paraoxonase activities. J. Neurochem. 90 (2005) 1216-1227
28. Furlong C.E., Holland N., Richter R.J., Bradman A., Ho A., and Eskenazi B. PON1 status of farm worker mothers and children as a predictor of organophosphate sensitivity. Pharmacogenet. Genom. 16 (2006) 183-190
29. Leviev I., and James R.W. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 516-521
30. Chen J., Chan W., Wallenstein S., Berkowitz G., and Wetmur J. Haplotype-phenotype relationships of paraoxonase 1. Cancer Epidemiol. Biomarkers Prev. 14 (2005) 731-734
31. O'Leary K.A., Edwards R.J., Town M.M., and Boobis A.R. Genetic and other sources of variation in the activity of serum paraoxonase/diazonase in humans: consequences for risk from exposure to diazinon. Pharmacogenet. Genom. 15 (2005) 51-60